Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

‘Unusual’ volume of CCCFA changes in focus
Finance

‘Unusual’ volume of CCCFA changes in focus

Select committee mulls proposed changes to CCCFA, to report recommendations Oct 20.

F&P Healthcare urges Govt to shut patent loophole
Markets

F&P Healthcare urges Govt to shut patent loophole

The company says the current patent loophole threatens its NZ operations.

NZX 50 dips despite Fletcher Building's 4.6% gain
Markets Market Close

NZX 50 dips despite Fletcher Building's 4.6% gain

Pacific Edge shares gained after it said it got a step closer to Medicare approval.

Gregor Thompson 15 Sep 2025
ANZ agrees to record A$240m fine for widespread misconduct
Markets

ANZ agrees to record A$240m fine for widespread misconduct

ANZ has agreed to pay the largest penalty its Australian regulator has ever issued an entity in one go, due to failings in the bank’s dealings with both the Government and its retail customers.ANZ and the Australian Securities and Investments Commission (ASIC) will ask the Federa...

Staff reporters 15 Sep 2025